CA88410L1022
© Newsfile
13.01.2026
TTI
LISTED
TSX
Thiogenesis Therapeutics' MELAS Abstract Accepted for Late-Breaking News Presentation at Mitocon 2026
News Preview
San Diego, California--(Newsfile Corp. - January 13, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation sulfur-based prodrugs for rare mitochondrial and metabolic diseases, today announced that an abstract outlining preliminary result...
Themefolio
Profiler
Peergroup
© Newsfile
05.01.2026
TTI
LISTED
TSX
Thiogenesis to Present Clinical Updates in MELAS and Leigh Syndrome Spectrum at UMDF Bench-to-Bedside Webinar
News Preview
Dr. Rioux Will Present on Phase 2 MELAS Program & Upcoming Phase 2a Leigh Syndrome TrialSan Diego, California--(Newsfile Corp. - January 5, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation sulfur-based prodrugs for rare mitochondria...
Themefolio
Profiler
Peergroup
© Newsfile
24.11.2025
TTI
LISTED
TSX
Thiogenesis Therapeutics Expands on Plans for Phase 3 Pivotal Trial of TTI-0102 in Nephropathic Cystinosis
News Preview
IND expected in early 2026; TTI-0102 designed to improve tolerability & simplify dosingSan Diego, California--(Newsfile Corp. - November 24, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation sulfur-based prodrugs for rare mitochondri...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Newsfile
04.11.2025
TTI
LISTED
TSX
Thiogenesis Reports Positive Interim Phase 2 Trial Results for MELAS and Announces Pipeline Advancements in Leigh Syndrome and Cystinosis
News Preview
Trial achieved biological proof-of-concept, dose discovery and biomarker improvementSan Diego, California--(Newsfile Corp. - November 4, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing sulfur-based therapeutics for pediatric diseases, predominantly...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Newsfile
03.10.2025
TTI
LISTED
TSX
Thiogenesis Announces Extension to Investor Relations Agreement
News Preview
San Diego, California--(Newsfile Corp. - October 3, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (Thiogenesis or the Company) a clinical-stage biotechnology company developing disulfides that drive the production of critically important intracellular antioxidants and other therapeutic compounds to treat unmet pediatric diseases, announces th...
Themefolio
Profiler
Peergroup
© Newsfile
11.09.2025
TTI
LISTED
TSX
Thiogenesis Reports on 2025 Annual General Meeting of Shareholders and Provides Corporate Update
News Preview
San Diego, California--(Newsfile Corp. - September 11, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biopharmaceutical company developing sulfur-based therapeutics for serious pediatric diseases, today announced the results of its Annual General Meeting of Shareholders ("AGM")...
Themefolio
Profiler
Peergroup
© Newsfile
14.08.2025
TTI
LISTED
TSX
Thiogenesis Receives Final Acceptance from TSXV for Its Over-Subscribed Non-Brokered Private Placement of Common Shares
News Preview
San Diego, California--(Newsfile Corp. - August 14, 2025) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is pleased to announce that, further to its news release of August 1, 2025, it has received final acceptance from the TSX Venture Exchange for its heavily over-subscribed non-brokered private placement (the "Offeri...
Themefolio
Profiler
Peergroup
© Newsfile
01.08.2025
TTI
LISTED
TSX
Thiogenesis Raises over C$4.14 Million in Non-Brokered Private Placement of Common Shares
News Preview
San Diego, California--(Newsfile Corp. - August 1, 2025) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is pleased to announce that, further to its news releases of July 17 and July 29, 2025, it has closed a heavily over-subscribed non-brokered private placement (the "Offering") through the issuance of 5,529,066 commo...
Themefolio
Profiler
Peergroup
© Newsfile
29.07.2025
TTI
LISTED
TSX
Thiogenesis Upsizes Fully Subscribed Non-Brokered Private Placement of Common Shares
News Preview
San Diego, California--(Newsfile Corp. - July 29, 2025) - Further to its news release of July 17, 2025, Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is very pleased to announce that, due to overwhelming investor demand, it has increased the size of a previously announced non-brokered private placement (the "Offering")...
Themefolio
Profiler
Peergroup
© Newsfile
17.07.2025
TTI
LISTED
TSX
Thiogenesis Announces Non-Brokered Private Placement of Common Shares
News Preview
San Diego, California--(Newsfile Corp. - July 17, 2025) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") announced today that it will undertake a non-brokered private placement (the "Offering") of 2,000,000 common shares of the Company ("Offered Shares") at a price of $0.75 per Common Share for gross proceeds of $1.5 mi...
Themefolio
Profiler
Peergroup
© Newsfile
25.06.2025
TTI
LISTED
TSX
Thiogenesis Receives Confirmatory Guidance on IMPD for Pediatric MASH Phase 2a Clinical Trial in Europe and Core Patent Granted in EU
News Preview
San Diego, California--(Newsfile Corp. - June 25, 2025) - Thiogenesis Therapeutics, Inc. (TSXV: TTI) (OTCQX: TTIPF), a clinical-stage biopharmaceutical company developing next-generation thiol-based therapies for mitochondrial disease and pediatric metabolic conditions, today announced that the Committee for Medicinal Products for Human Use ("CHMP...
Themefolio
Profiler
Peergroup
© Newsfile
20.06.2025
TTI
LISTED
TSX
Thiogenesis Therapeutics to Present at UMDF's Mitochondrial Medicine 2025 Conference
News Preview
Dr. Rioux to Highlight Industry-Leading Clinical Programs in MELAS and Leigh Syndrome SpectrumSan Diego, California--(Newsfile Corp. - June 20, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biopharmaceutical company developing sulfur-based therapeutics for rare pediatric and in...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Newsfile
17.06.2025
TTI
LISTED
TSX
Thiogenesis Announces Second Site Begins Enrolling in Phase 2 MELAS Clinical Trial and Provides Update
News Preview
San Diego, California--(Newsfile Corp. - June 17, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biopharmaceutical company developing sulfur-based therapeutics for serious pediatric and inherited mitochondrial diseases, today announced the recent activation of its French clinical...
Themefolio
Profiler
Peergroup
© Newsfile
12.06.2025
TTI
LISTED
TSX
Thiogenesis Announces Grant of Stock Options
News Preview
San Diego, California--(Newsfile Corp. - June 12, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that drive the production of critically important intracellular antioxidants and other therapeutic compounds, announces that pursuant to th...
Themefolio
Profiler
Peergroup
© Newsfile
11.06.2025
TTI
LISTED
TSX
Thiogenesis Announces FDA Clearance of its Investigational New Drug Application ("IND") for a Phase 2a Clinical Trial in Leigh Syndrome Spectrum
News Preview
San Diego, California--(Newsfile Corp. - June 11, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ('Thiogenesis' or the 'Company') a clinical-stage biotechnology company developing disulfides that drive the production of intracellular cysteine, an amino acid that is a critical precursor to the generation of the master antioxidan...
Themefolio
Profiler
Peergroup
© Newsfile
14.05.2025
TTI
LISTED
TSX
Thiogenesis Initiates Phase 2 Clinical Trial in Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like Episodes ("MELAS")
News Preview
San Diego, California--(Newsfile Corp. - May 14, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that drive the production of critically important intracellular antioxidants and other therapeutic compounds, today announced that it has do...
Themefolio
Profiler
Peergroup
© Newsfile
20.02.2025
TTI
LISTED
TSX
Thiogenesis Announces European Consulting and Investor Relations Agreement
News Preview
San Diego, California--(Newsfile Corp. - February 20, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that drive the production of critically important intracellular antioxidants and other therapeutic compounds, today announced that it h...
Themefolio
Profiler
Peergroup
© Newsfile
12.02.2025
TTI
LISTED
TSX
Thiogenesis Announces Commencement of OTCQX Trading in the U.S.
News Preview
San Diego, California--(Newsfile Corp. - February 12, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that drive the production of critically important intracellular antioxidants and other therapeutic compounds, today announced that its...
Themefolio
Profiler
Peergroup
© Newsfile
27.01.2025
TTI
LISTED
TSX
Thiogenesis Receives Final EU Clearance of CTA to Initiate its Phase 2 Clinical Trial in MELAS
News Preview
San Diego, California--(Newsfile Corp. - January 27, 2025) - Thiogenesis Therapeutics, and Corp. (TSXV: TTI) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing disulfides that drive the production of critically important intracellular antioxidants and other therapeutic compounds, today announced that the European Me...
Themefolio
Profiler
Peergroup
© Newsfile
10.12.2024
TTI
LISTED
TSX
Thiogenesis Announces Presentation on UMDF Webcast Featuring Clinical Trials in Mitochondrial Disease
News Preview
San Diego, California--(Newsfile Corp. - December 10, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing novel thiol compounds, including precursors to cysteamine, that have potent antioxidant and anti-inflammatory properties for mitochondrial diseases and related m...
Themefolio
Profiler
Peergroup
© Newsfile
28.11.2024
TTI
LISTED
TSX
Thiogenesis Announces DTC Eligibility in the U.S. and Other Updates
News Preview
San Diego, California--(Newsfile Corp. - November 28, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTC: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing novel thiol compounds, that includes precursors to cysteamine and that have potent antioxidant and anti-inflammatory properties for the treatment of...
Themefolio
Profiler
Peergroup
© Newsfile
04.11.2024
TTI
LISTED
TSX
Thiogenesis Announces Important Core Patent Allowed in Europe
News Preview
San Diego, California--(Newsfile Corp. - November 4, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing novel thiol compounds, including precursors to cysteamine that have potent antioxidant and anti-inflammatory properties for mitochondrial diseases and related...
Themefolio
Profiler
Peergroup
© Newsfile
27.09.2024
TTI
LISTED
TSX
Thiogenesis Announces Investor Relations Engagement
News Preview
San Diego, California--(Newsfile Corp. - September 27, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (Thiogenesis or the Company) a clinical-stage biotechnology company developing thiol-active compounds that have strong antioxidant and anti-inflammatory properties and that have the potential to treat mitochondrial diseases, including metaboli...
Themefolio
Profiler
Peergroup
© Newsfile
17.09.2024
TTI
LISTED
TSX
Thiogenesis Announces Presentation at 3rd Annual Leigh Syndrome Symposium
News Preview
San Diego, California--(Newsfile Corp. - September 17, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that are precursors to thiol-active compounds and potent antioxidants targeting unmet pediatric diseases, today announced that Patrice Rioux, M.D., P...
Themefolio
Profiler
Peergroup
© Newsfile
20.08.2024
TTI
LISTED
TSX
Thiogenesis Announces Collaboration and Updates on Pediatric NASH Clinical Program
News Preview
San Diego, California--(Newsfile Corp. - August 20, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that are precursors to thiol-active compounds and potent antioxidants targeting unmet pediatric diseases, today announced that it has signed a Collabora...
Themefolio
Profiler
Peergroup
© Newsfile
18.07.2024
TTI
LISTED
TSX
Thiogenesis Announces Leigh Syndrome Clinical Program
News Preview
San Diego, California--(Newsfile Corp. - July 18, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that are precursors to thiol-active compounds and potent antioxidants targeting unmet pediatric diseases, today announced that it has signed a Master Rese...
Themefolio
Profiler
Peergroup
© Newsfile
25.03.2024
TTI
LISTED
TSX
Thiogenesis Announces Acceptance of Clinical Trial Application - Part I in the EU for MELAS
News Preview
San Diego, California--(Newsfile Corp. - March 25, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that are precursors to thiol-active compounds and that have the potential to treat unmet pediatric diseases, today announced that the European Medici...
Themefolio
Profiler
Peergroup
© Newsfile
20.12.2023
TTI
LISTED
TSX
Thiogenesis Announces Closing of Final Tranche in $4.5 Million Non-Brokered Private Placement
News Preview
San Diego, California--(Newsfile Corp. - December 20, 2023) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is very pleased to announce that, further to its news release of December 18, 2023, it has closed a second and final tranche of its non-brokered private placement, originally announced on November 20, 2023 (the...
Themefolio
Profiler
Peergroup
© Newsfile
18.12.2023
TTI
LISTED
TSX
Thiogenesis Announces Closing of Non-Brokered Private Placement of Common Shares and Insider Participation
News Preview
San Diego, California--(Newsfile Corp. - December 18, 2023) - Further to its news release of November 20, 2023, Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is very pleased to announce that it has closed a non-brokered private placement (the "Offering") through the issuance of 5,584,167 common shares (the "Offered Sh...
Themefolio
Profiler
Peergroup
© Newsfile
04.12.2023
TTI
LISTED
TSX
Thiogenesis CEO Invited to Lead a Round Table Discussion at Influential Mitochondria Symposium
News Preview
San Diego, California--(Newsfile Corp. - December 4, 2023) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company that is developing sulfur-containing compounds for unmet pediatric diseases, announced today that its CEO, Dr. Patrice Rioux, has been invited to lead a roundtable discussion...
Themefolio
Profiler
Peergroup
© Newsfile
27.11.2023
TTI
LISTED
TSX
Thiogenesis Announces Addition of Dr. Vince Stanton Jr. to Its Scientific Advisory Board
News Preview
San Diego, California--(Newsfile Corp. - November 27, 2023) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing sulfur-containing therapeutics for unmet pediatric diseases, today announced the addition of Vincent Stanton Jr., MD to its Scientific Advisory Board ("SAB"). Dr...
Themefolio
Profiler
Peergroup
© Newsfile
20.11.2023
TTI
LISTED
TSX
Thiogenesis Announces Non-Brokered Private Placement of Common Shares
News Preview
San Diego, California--(Newsfile Corp. - November 20, 2023) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") announced today that it will undertake a non-brokered private placement of $4.5 million (the "Offering") through the issuance of 6,000,000 common shares of the Company ("Offered Shares") at a price of $0.75 per C...
Themefolio
Profiler
Peergroup
© Newsfile
10.05.2023
TTI
LISTED
TSX
Thiogenesis Therapeutics Reports on Full Year 2022 Financial Results and Provides Corporate Update
News Preview
San Diego, California--(Newsfile Corp. - May 10, 2023) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing thiol-active compounds for unmet pediatric diseases, today reports on full year 2022 financial results and provides a corporate update.Patrice Rioux, M.D., Ph.D., Thio...
Themefolio
Profiler
Peergroup
© Newsfile
09.12.2022
TTI
LISTED
TSX
Thiogenesis Announces Stock Option Grants
News Preview
San Diego, California--(Newsfile Corp. - December 9, 2022) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is pleased to announce that it has granted an aggregate of 450,000 incentive stock options (the "Options") pursuant to the Company's stock option plan of which 350,000 were granted to directors and officers and 1...
Themefolio
Profiler
Peergroup
© Newsfile
21.11.2022
TTI
LISTED
TSX
Thiogenesis Announces Closing of Oversubscribed $5.3 Million Non-Brokered Private Placement
News Preview
San Diego, California--(Newsfile Corp. - November 21, 2022) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is pleased to announce today, further to its news releases of October 24 and November 2, 2022, that it has closed an over-subscribed non-brokered private placement (the "Offering") through the issuance of 10,61...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
